These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 22402822)

  • 1. The impact of PET and PET/CT on treatment planning and prognosis of patients with NSCLC treated with radiation therapy.
    Nawara C; Rendl G; Wurstbauer K; Lackner B; Rettenbacher L; Datz L; Studnicka M; Sedlmayer F; Pirich C
    Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):191-201. PubMed ID: 22402822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of FDG PET/CT on delineation of the gross tumor volume for radiation planning in non-small-cell lung cancer.
    Spratt DE; Diaz R; McElmurray J; Csiki I; Duggan D; Lu B; Delbeke D
    Clin Nucl Med; 2010 Apr; 35(4):237-43. PubMed ID: 20305410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
    Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
    Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate?
    Biehl KJ; Kong FM; Dehdashti F; Jin JY; Mutic S; El Naqa I; Siegel BA; Bradley JD
    J Nucl Med; 2006 Nov; 47(11):1808-12. PubMed ID: 17079814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives.
    Nestle U; Kremp S; Grosu AL
    Radiother Oncol; 2006 Nov; 81(2):209-25. PubMed ID: 17064802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of computed tomography (CT) and 18F-deoxyglucose-coincidence detection emission tomography (FDG-CDET) image fusion for optimisation of conformal radiotherapy in non-small-cell lung cancers].
    Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
    Cancer Radiother; 2005 Sep; 9(5):304-15. PubMed ID: 16087377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stage migration in planning PET/CT scans in patients due to receive radiotherapy for non-small-cell lung cancer.
    Geiger GA; Kim MB; Xanthopoulos EP; Pryma DA; Grover S; Plastaras JP; Langer CJ; Simone CB; Rengan R
    Clin Lung Cancer; 2014 Jan; 15(1):79-85. PubMed ID: 24238934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
    Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.
    Liao S; Penney BC; Zhang H; Suzuki K; Pu Y
    Acad Radiol; 2012 Jan; 19(1):69-77. PubMed ID: 22142679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients.
    Ohno Y; Koyama H; Nogami M; Takenaka D; Yoshikawa T; Yoshimura M; Ohbayashi C; Sugimura K
    J Magn Reson Imaging; 2007 Oct; 26(4):1071-80. PubMed ID: 17896365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
    Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
    J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The variation of prognostic significance of Maximum Standardized Uptake Value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected Non-Small Cell Lung Carcinoma.
    Casali C; Cucca M; Rossi G; Barbieri F; Iacuzio L; Bagni B; Uliano M
    Lung Cancer; 2010 Aug; 69(2):187-93. PubMed ID: 19942313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline SUVmax at PET-CT in stage IIIA non-small-cell lung cancer patients undergoing surgery after neoadjuvant therapy: prognostic implication focused on histopathologic subtypes.
    Lee HY; Lee KS; Park J; Han J; Kim BT; Kwon OJ; Ahn YC; Ahn MJ; Park K; Kim J; Shim YM
    Acad Radiol; 2012 Apr; 19(4):440-5. PubMed ID: 22265854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: a prospective population-based study.
    De Ruysscher D; van Baardwijk A; Steevens J; Botterweck A; Bosmans G; Reymen B; Wanders R; Borger J; Dingemans AM; Bootsma G; Pitz C; Lunde R; Geraedts W; Oellers M; Dekker A; Lambin P
    Radiother Oncol; 2012 Feb; 102(2):228-33. PubMed ID: 22100659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer.
    Cerfolio RJ; Ojha B; Bryant AS; Raghuveer V; Mountz JM; Bartolucci AA
    Ann Thorac Surg; 2004 Sep; 78(3):1017-23; discussion 1017-23. PubMed ID: 15337041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of serial [18F]fluorodeoxyglucose PET-CT uptake in stage III patients with non-small cell lung cancer treated by concurrent chemoradiotherapy.
    Zhang HQ; Yu JM; Meng X; Yue JB; Feng R; Ma L
    Eur J Radiol; 2011 Jan; 77(1):92-6. PubMed ID: 19695804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementing biologic target volumes in radiation treatment planning for non-small cell lung cancer.
    Bradley JD; Perez CA; Dehdashti F; Siegel BA
    J Nucl Med; 2004 Jan; 45 Suppl 1():96S-101S. PubMed ID: 14736840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
    Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
    Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams.
    Bahri S; Flickinger JC; Kalend AM; Deutsch M; Belani CP; Sciurba FC; Luketich JD; Greenberger JS
    Radiat Oncol Investig; 1999; 7(5):297-308. PubMed ID: 10580899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role.
    Vesselle H; Freeman JD; Wiens L; Stern J; Nguyen HQ; Hawes SE; Bastian P; Salskov A; Vallières E; Wood DE
    Clin Cancer Res; 2007 Jun; 13(11):3255-63. PubMed ID: 17545531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.